LEGN Stock — Legend Biotech Corporation

Legend Biotech Corporation (LEGN)

Updated October 16, 2026.

LEGN is a Stock. Total return is -50.1% over the past 6.4 years, 211.4 points behind SPY at 161.3%.

Legend Biotech Corporation is a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications, with its lead product being cilta-cel, a CAR-T therapy for multiple myeloma developed in collaboration with Janssen Biotech. The company does not currently distribute to shareholders. Legend Biotech appeals to growth-oriented investors seeking exposure to clinical-stage and commercializing cell therapy companies, with no established income component.

LEGN performance versus SPY

Price and return data through 2026-10-16.

Total return is -50.1% over the past 6.4 years, 211.4 points behind SPY at 161.3%. Over the past year its total return — price change plus distributions reinvested — is -42.9%. Its deepest 1-year drawdown was 53.1%.

LEGN key facts

Asset type

Stock

Asset class

Equity

Inception date

06/05/2020

Distribution frequency

None

Last close

$18.48 (as of 2026-10-16)

Market cap

$3,594,145,872

Average volume

2961655.0

Beta

0.573

Payout ratio

0.0%

Forward P/E

27.5482

EPS

$-0.52

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LEGN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 53.1%.

Who may consider LEGN — and who may not

It is a weaker fit for investors who need monthly cash flow (LEGN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LEGN

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions